1.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
2.	Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: GCO 09-1300-00002, P01CA108671, MPD-RC 112, NCT01259856
3.	Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PERSIST-1 (PAC325), NCT01773187
4.	Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2012-0737, NCT01787487
5.	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
6.	Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
7.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
8.	Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-0132, NCT00943319
9.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
10.	Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RGI-2001-02, NCT01379209
11.	Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-001, NCT01416428
12.	Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 201303012, NCT01747499
13.	Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Phase: Phase II Type: Treatment Status: Active Age: 8 to 80 Sponsor: NHLBI Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
14.	Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 75 Sponsor: NCI Protocol IDs: 040055, 04-C-0055, NCI-04-C-0055, NCT00077480, NCT00074490
15.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
16.	Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Phase: Phase II Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2056.00, NCI-2010-00237, P01HL036444, P01CA078902, FHCRC-2056.00, 6171, NCT00397813
17.	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Phase: Phase II Type: Treatment Status: Active Age: 10 to 75 Sponsor: NHLBI Protocol IDs: NHLBI-06-H-0248, NHLBI-IDE-13058, NCT00398346
18.	Laboratory-Treated T Lymphocytes in Preventing Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Stem Cell Transplant for Hematologic Cancer or Other Disease Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: NHLBI Protocol IDs: NHLBI-07-H-0136, 07-H-0136
19.	Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and under Sponsor: NCI, Other Protocol IDs: 2212.00, NCI-2009-01244, P01CA018029, U19AI096111, NCT00968630
20.	T-cell Depleted Alternative Donor Transplantation Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: LCH BMT 09-01, NCT00968864
21.	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 0 to 75 Sponsor: NCI, Other Protocol IDs: 2241.00, NCI-2009-01334, P01CA078902, NCT01008462
22.	Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0284, NCT01200485
23.	Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 2206.00, NCI-2010-02222, P01CA018029, NCT01251575
24.	Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: GCO 09-1300 001, P01CA108671, MPD-RC 111, NCT01259817
25.	Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: UCBT01, NCT01328496